NCT07128680
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07128680
Title Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.